133 related articles for article (PubMed ID: 17111243)
1. Use and costs of anti-secretory and cardiovascular co-medication in osteoarthritis patients treated with selective or non-selective NSAIDS.
Simoens S; De Coster S; De Ruyck B; Stutz P; Laekeman G
Pharm World Sci; 2006 Oct; 28(5):309-17. PubMed ID: 17111243
[TBL] [Abstract][Full Text] [Related]
2. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands.
Al MJ; Maniadakis N; Grijseels EW; Janssen M
Value Health; 2008; 11(4):589-99. PubMed ID: 18194404
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
4. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective].
De Lossada A; Oteo-Álvaro Á; Giménez S; Oyagüez I; Rejas J
Semergen; 2016; 42(4):235-43. PubMed ID: 26006311
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoutilization and costs of osteoarthritis: changes induced by the introduction of a cyclooxygenase-2 inhibitor into clinical practice.
Russo P; Capone A; Attanasio E; Baio G; Di Martino M; Degli Esposti L; Marchetta F; Buda S; Degli Esposti E; Caprino L
Rheumatology (Oxford); 2003 Jul; 42(7):879-87. PubMed ID: 12730549
[TBL] [Abstract][Full Text] [Related]
8. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
Watson DJ; Bolognese JA; Yu C; Krupa D; Curtis S
Curr Med Res Opin; 2004 Dec; 20(12):1899-908. PubMed ID: 15701208
[TBL] [Abstract][Full Text] [Related]
9. Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study.
Lapi F; Piccinni C; Simonetti M; Levi M; Lora Aprile P; Cricelli I; Cricelli C; Fanelli A
Intern Emerg Med; 2016 Feb; 11(1):49-59. PubMed ID: 26271463
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
Watson DJ; Harper SE; Zhao PL; Bolognese JA; Simon TJ
MedGenMed; 2001 Nov; 3(4):6. PubMed ID: 11965201
[TBL] [Abstract][Full Text] [Related]
11. Nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis.
Jobanputra P; Nuki G
Curr Opin Rheumatol; 1994 Jul; 6(4):433-9. PubMed ID: 8068516
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
[TBL] [Abstract][Full Text] [Related]
13. Risk of Acute Cerebrovascular and Cardiovascular Events Among Users of Acetaminophen or an Acetaminophen-Codeine Combination in a Cohort of Patients with Osteoarthritis: A Nested Case-Control Study.
Roberto G; Simonetti M; Piccinni C; Lora Aprile P; Cricelli I; Fanelli A; Cricelli C; Lapi F
Pharmacotherapy; 2015 Oct; 35(10):899-909. PubMed ID: 26497476
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
15. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
Rahme E; Toubouti Y; Hunsche E
Rheumatology (Oxford); 2006 Jul; 45(7):903-10. PubMed ID: 16461440
[TBL] [Abstract][Full Text] [Related]
16. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.
Lee MC; Lee S; Suh DC; Kim J; Kong SX;
Curr Med Res Opin; 2003; 19(7):597-602. PubMed ID: 14606981
[TBL] [Abstract][Full Text] [Related]
17. Medical costs of chronic musculoskeletal pain in Italy.
Garattini L; Koleva D; Motterlini N; Cornago D
Clin Drug Investig; 2007; 27(2):139-48. PubMed ID: 17217319
[TBL] [Abstract][Full Text] [Related]
18. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
Joshua FF; Oakley SP; Major GA
Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
[TBL] [Abstract][Full Text] [Related]
19. Should osteoarthritis be treated with nonsteroidal anti-inflammatory drugs?
Brandt KD
Rheum Dis Clin North Am; 1993 Aug; 19(3):697-712. PubMed ID: 8210582
[TBL] [Abstract][Full Text] [Related]
20. The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis.
Yilmaz H; Gürel S; Ozdemir O
Turk J Gastroenterol; 2005 Sep; 16(3):138-42. PubMed ID: 16245223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
